CARA stock is on fire as Cara Therapeutics Inc (NASDAQ:CARA) reported positive topline results from a Phase 3 clinical trial, KALM-1, evaluating KORSUVA.
Cara’s KORSUVA SuccessfulAs far as therapeutics companies are concerned, the completion of key milestones with regards to a product is essential for the company’s growth, and Stamford, Connecticut-based Cara Therapeutics announced that the company’s lead candidate has completed a major milestone.
It is believed that following the completion of this milestone, the company’s hopes of getting the United States Food and Drug Administration (FDA) approval for the product has also ...
Read The Full Article On MicroSmallCap.com
Get early insight on hidden secret gems on MicroSmallCap. Follow Crypto, Mining, Cannabis and Energy stocks and get free research reports here.
All content provided by MicroSmallCap is subject to our Terms Of Use and Disclaimer.